The Evolution of Clinical Trial Design, Optimization, and Execution in the Age of AI and Autonomous Systems
- maurinabignotti
- May 28
- 10 min read
May 2026
Executive Summary
Clinical development is at an inflection point. Since the adoption of Electronic Data Capture, the industry has focused primarily on execution efficiency, optimizing CROs, site networks, and operational workflows. That paradigm is giving way to something more fundamental: designing better trials before they begin and ultimately getting much-needed medicines and therapies to patients faster.
The convergence of Artificial Intelligence, Real-World Data, Electronic Health Records, predictive modeling, and digital twin technologies is enabling a new generation of clinical technology companies to attack the problem upstream, at the level of trial design, protocol feasibility, patient identification, and outcome prediction. The question is no longer just how fast we can run this trial, but are we running the right trial at all.
The Problem
Roughly 90% of drug candidates fail before approval. Recruitment delays remain the leading cause of trial disruption. Protocol complexity continues to grow, while overly restrictive eligibility criteria systematically exclude the very patients a therapy was designed to help. The result: trials that are underpowered, overcomplicated, or fundamentally misaligned with the real-world populations they are meant to serve, and a development process that remains among the most expensive and highest-risk endeavors in any industry.
AI-enabled clinical trial technologies, spanning trial simulation, adaptive optimization, real-world evidence generation, digital twins, and clinical decision intelligence, are projected to expand significantly over the next decade as sponsors seek to compress timelines, improve success rates, and reduce the cost of bringing therapies to market. Beyond optimizing trial execution, these technologies are enabling a fundamental shift toward in silico-first drug development, where clinical, biological, and patient-derived data are used earlier in the discovery and design process to inform the development of molecules, medicines, and therapies with a higher probability of clinical success. By leveraging advanced modeling, simulation, human biology insights, and real-world evidence, organizations can increasingly identify and mitigate risks associated with off-target effects, toxicity, potential adverse events, and patient variability before entering the clinic, ultimately improving the efficiency, predictability, and success rate of therapeutic development.
Emerging Market Segments
__________________________________________________________________________________
The clinical trial optimization landscape is rapidly organizing around four (4) major categories:
1. AI-Native Clinical Operations Platforms
Rather than layering technology onto traditional processes, these companies build clinical operations around software, automation, and AI from the outset, reinventing the CRO model itself. Key capabilities span protocol design support, recruitment optimization, trial management, centralized monitoring, real-time operational visibility, and AI-assisted decision-making.
2. Patient Recruitment & Matching Platforms
Historically one of the largest bottlenecks in drug development, recruitment is now being transformed by platforms that leverage EHR data, genomics, real-world evidence, and AI-powered patient matching to achieve a single goal: Find the right patient, at the right site, at the right time.
3. Trial Simulation & Digital Twins
Arguably the most disruptive emerging category. Instead of running physical experiments first, sponsors can now simulate enrollment scenarios, eligibility criteria changes, endpoint selection, visit schedules, statistical outcomes, and protocol modifications, before spending millions on actual execution. Digital twin technologies are increasingly viewed as mechanisms to improve trial design, reduce risk, and predict outcomes before a single patient is enrolled.
4. AI-Powered Clinical Intelligence Platforms
These platforms combine clinical data, molecular data, EHRs, outcomes data, and real-world evidence to generate insights that improve both trial design and execution. The strategic question shifts from
“Can we run this trial?” → “Should we run this trial this way?”
Leading Company Perspectives
__________________________________________________________________________________
1. Evinova AstraZeneca’s AI-Native Clinical Platform, Scaled From Within |
Evinova is a significant entrant in the clinical trial technology space, not because it was built from scratch by a startup, but because it was built from the inside out, by AstraZeneca, one of the world’s largest pharmaceutical companies. Launched in November 2023 as a standalone health-tech business operating within the AstraZeneca group, Evinova’s founding thesis is distinctive: take the digital solutions AstraZeneca developed and battle-tested across its own global drug development pipeline and offer them to the broader industry. Its portfolio is evidence-led, science-based, and human experience-driven, built with input from thousands of patients and clinical researchers across nine countries. Core Platform Capabilities
Ecosystem & Partnerships Evinova launched with strategic CRO partnerships with Parexel and Fortrea, enabling its solutions to reach a wide customer base immediately. By early 2026, it had announced expanded collaborations with Astellas, AstraZeneca (as a customer), and Bristol Myers Squibb, and just recently GeneScience Pharmaceuticals, signaling rapid adoption across major pharma. AWS is supporting scalability and global deployment. Strategic Position Evinova occupies a rare position in this market: it combines the credibility of a large pharma organization with the agility mandate of an independent health-tech company. Rather than losing a competitive advantage by sharing its playbook, AstraZeneca has chosen to monetize it. Evinova is one of the clearest examples yet of a major sponsor operationalizing the belief that the future of clinical development is platform-driven, patient-centric, and AI-enabled, and betting that the industry will follow. |
2. Lindus Health The “Accountable Research Organization” |
Lindus Health positions itself as an “Accountable Research Organization”, or anti-CRO, rather than a traditional CRO, its thesis being that CRO incentives have historically been misaligned with sponsor outcomes. Founded in 2021 and headquartered in London, Lindus addresses this through its proprietary Citrus™ eClinical platform, AI-native clinical operations, performance-oriented commercial models (fixed-price, milestone-based), in-house recruitment capabilities, and real-time trial visibility. The company has access to more than 40 million EHRs and has operated 42 end-to-end clinical trials enrolling over 36,000 patients across North America and Europe, spanning psychiatry, diagnostics, and respiratory health.
In January 2025, Lindus closed a $55M Series B round led by Balderton Capital, with participation from Visionaries Club, Creandum, Firstminute, and Seedcamp. The round is directed at deepening the Citrus™ platform, with capabilities spanning AI-driven protocol design, automated central monitoring, instant biostatistics, and recruitment optimization. According to company metrics, Lindus has demonstrated trials running up to three times faster than traditional players with demonstrably better data quality. In April 2025, the company was awarded funding by ARIA (the UK’s Advanced Research and Invention Agency) as part of its Safeguarded AI program, to develop safe and reliable AI for clinical trial design in collaboration with the University of Oxford’s Department of Computer Science. Its strategic advisory board includes Robert S. Langer (founder of Moderna) and Tim Garnett (former CMO of Eli Lilly). Strategic Position Lindus represents the evolution of the CRO into a software-enabled operating system for clinical development. |
3. Tempus + Deep 6 AI Building the Clinical Trial Recruitment Engine |
Tempus AI (NASDAQ: TEM) has built one of the most important AI platforms in healthcare through the practical application of machine learning across clinical and molecular data, primarily in oncology, genomics, and precision medicine. In March 2025, Tempus acquired Deep 6 AI, an AI-driven clinical trial recruitment platform integrated with over 750 provider site locations spanning more than 30 million patients, including academic medical centers, NCI-Designated Cancer Centers, and NCI Community Oncology Research Programs. Deep 6’s platform identifies eligible trial candidates by mining real-time structured data (ICD-10 codes, demographics) and unstructured data (physician notes, lab results, imaging findings) from electronic medical records, identifying over 25% more eligible patients compared to traditional methods and accelerating recruitment up to three times faster. The acquisition extends Tempus beyond precision medicine and genomics into operational clinical development. The combined platform integrates Tempus’ Next application, an AI tool that analyzes multimodal longitudinal patient data including imaging, EMR data, lab results, pathology reports, and clinician notes across oncology and cardiology, with Deep 6’s TIME trial program for rapid patient identification and enrollment. Tempus also completed the $600M acquisition of Ambry Genetics (finalized February 2025), reinforcing its focus on genetic-based precision medicine and creating a powerful combination of clinical data, molecular data, patient populations, and trial matching intelligence at a scale few competitors can match. Strategic Position Tempus is becoming a foundational data and intelligence layer for precision clinical research. |
4. Biorce Simulation-Driven Clinical Development |
Biorce, founded in 2024 and headquartered in Barcelona, represents one of the most compelling emerging categories: AI-powered clinical trial design and protocol intelligence. The company’s flagship platform, Aika, is trained on a database of more than one million clinical studies and helps research teams simulate trial models, identify regulatory risks, and reduce protocol design time by up to 50%. Its headline capability: generating regulator-ready protocols in 90 seconds with 86% accuracy.1 Biorce directly targets one of clinical development’s most costly failure modes, protocol amendments, which affect approximately 60% of all trials and cost an average of $250,000 to $450,000 each. The platform has already streamlined over 300 clinical trial protocols across oncology and neurology. Investor conviction in Biorce has been rapid. The company raised €3.5M in November 2024, a €5M extension from Norrsken VC in summer 2025, and closed a $52.5M Series A in February 2026, led by DST Global Partners and described as the largest Series A in Iberian healthtech and AI history, bringing total funding to over $60M. The round included prominent angel investors such as Nik Storonsky (CEO of Revolut) and Arthur Mensch (CEO of Mistral AI). Biorce ended 2025 approximately 200% above its revenue target. The company is now expanding aggressively into the US market, positioning Aika as the protocol intelligence standard for global pharma and CRO operations. Strategic Position Biorce sits at the leading edge of the shift from trial execution toward trial prediction. |
5. Luminari CRO AI-Enabled Clinical Trial Intelligence |
Founded in October 2024 and headquartered in Miami, Florida, Luminari CRO is an ambitious AI-native entrant in clinical development. Where many companies apply AI as a layer on top of conventional CRO operations, Luminari was architected from day one around a single thesis: the entire drug development workflow, from protocol generation to patient recruitment to regulatory submission, can be fundamentally redesigned using AI. The company’s leadership team brings over 100 years of combined experience from organizations including Apple, IBM, CVS Health, Parexel, and IQVIA, and includes former FDA and EU regulators. That regulatory depth is not incidental; it is central to Luminari’s product strategy. LumiPath™, The Core Innovation Luminari’s flagship product, LumiPath™, is a multi-agent AI platform that generates regulatory-compliant clinical trial protocols in minutes rather than weeks. Trained on thousands of successful protocols across therapeutic areas, it produces complete submissions that meet FDA, EMA, and ICH standards, including optimized statistical designs, comprehensive safety monitoring plans, and operational execution frameworks. Protocol amendments are one of the most costly and time-consuming problems in clinical development, afflicting roughly 60% of all trials. LumiPath™ directly targets this failure mode by stress-testing design decisions before a single patient is enrolled. The company’s headline metric: what took 8 weeks now takes 8 minutes. The Full Product Suite
Measured Impact Luminari publishes specific performance targets against its platform: 50% faster clinical trial timelines, 30% reduction in development costs, 2x improvement in patient recruitment, and 95% data integrity through blockchain-secured immutable trial records. These are bold claims for an early-stage company, and they reflect the ambition of a team that has lived the pain points from both the sponsor and regulatory sides of the table. Where Luminari Fits in the Landscape Most clinical AI companies pick one problem to solve, recruitment, or protocol design, or monitoring. Luminari is attempting to own the full intelligent development stack: from the moment a protocol is conceived, through patient identification, enrollment, execution, and regulatory submission. If the platform delivers at scale, it represents not just a better CRO, but a redefinition of what a CRO can be. Currently raising a pre-seed round to scale its platform, expanding LLM model training, and grow its go-to-market capabilities, Luminari is at an early but pivotal stage. Strategic Position Luminari is building toward a world where clinical development intelligence is continuous, predictive, and end-to-end, not episodic and reactive. It is one of the clearest expressions in the market of the shift from trial execution to trial design, and from human-led process management to AI-orchestrated drug development. |
Where the Industry Is Going: A Five-Phase Evolution
__________________________________________________________________________________
The next decade will likely see clinical development evolve through five distinct stages, from today’s digital trials to a future where simulation precedes execution:
Phase | Stage | Status | Key Capabilities |
Phase 1 | Digital Trials | Current | EDC · ePRO · eConsent · Remote Monitoring |
Phase 2 | AI-Assisted Trials | Transition | Recruitment Optimization · Predictive Enrollment · Site Selection · Protocol Review |
Phase 3 | Simulation-Driven Trials | Emerging | Virtual Populations · Protocol Simulation · Digital Twins · Feasibility Prediction |
Phase 4 | Autonomous Optimization | Near Future | Continuous Refinement · Dynamic Enrollment · AI-Guided Study Management |
Phase 5 | In Silico-First Development | Long-Term Vision | Full simulation before first patient · Design, risk, endpoint, and recruitment all pre-validated |
In Silico-First clinical development represents the long-term vision: before enrolling the first patient, study designs are simulated, populations modeled, risks predicted, endpoints optimized, and recruitment pathways validated. Only then does physical execution begin.
20/15 Visioneers Perspective
__________________________________________________________________________________
The clinical trial industry is on a trajectory like the one R&D laboratories followed over the past two decades:
Digitize the workflow
Standardize the process
Integrate the data
Apply AI
Enable predictive decision-making
The winners will not simply be organizations with the most AI, they will be organizations that combine:
The highest quality, FAIR+T-aligned data foundations
Strong process governance
Integrated clinical and real-world data ecosystems
Explainable AI frameworks
Simulation and digital twin capabilities
Our View:
The future of clinical development is not merely faster execution. It is designing better clinical trials before they are ever run. From Trial-and-Error to Trial-by-Design. And most importantly, the translational approach to drug discovery will allow for much better failure-proofed medicines and therapies!
__________________________________________________________________________________
20/15 Visioneers
“World Leaders in Biopharma Consulting, Marketing, and Staffing”
Comments